DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.
about
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyImmunotherapy for prostate cancer: recent developments and future challengesDNA vaccine for cancer immunotherapyPreclinical and clinical development of DNA vaccines for prostate cancer.DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responsesImmunotherapy for the treatment of prostate cancer.Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response.T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockadeProposed mechanisms of action for prostate cancer vaccines.Trial watch: Naked and vectored DNA-based anticancer vaccinesDNA vaccines, electroporation and their applications in cancer treatmentDemystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Therapeutic cancer vaccines: the latest advancement in targeted therapy.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Development of animal models underlining mechanistic connections between prostate inflammation and cancerImmunotherapy for prostate cancer: biology and therapeutic approachesImmunotherapy and immune evasion in prostate cancer.Sipuleucel-T: immunotherapy for advanced prostate cancer.DNA Vaccines for Prostate Cancer.Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.Recent advances in immunotherapy for the treatment of prostate cancer.Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.A molecular description of acid phosphatase.Prostate cancer vaccines in clinical trials.Prostate cancer vaccines.Beyond sipuleucel-T: immune approaches to treating prostate cancer.Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.Prostate cancer vaccines in combination with additional treatment modalities.Therapeutic vaccines for cancer: an overview of clinical trials.Molecular insights into the development of T cell-based immunotherapy for prostate cancer.Immunotherapy in prostate cancer: review of the current evidence.DNA vaccination for prostate cancer: key concepts and considerations.Immunotherapy in prostate cancer: challenges and opportunities.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.Recent progress in GM-CSF-based cancer immunotherapy.Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.Prostate cancer vaccines: Update on clinical development.
P2860
Q26851608-49714301-6659-4BCD-A6EF-3E3875CD8FF9Q26852388-38752134-6CB7-44C5-AFAA-27A9EDF5AE87Q28080919-FA28A162-92FC-468C-A07A-ECEE3A16CF69Q33740811-62115883-8F36-4855-9DC9-BF920EC506FAQ34127323-B44504BD-E7F7-415C-B835-5EE176810677Q34186928-E25C84CF-01E2-4B5B-8C42-12244E26D2E3Q34243390-58463F08-5D52-4A9D-A2FE-17AEAB2D54DCQ34522301-69CEA5CF-A03B-4867-8A0E-3E5E84722CEDQ34577158-49924FE6-C4D7-4C65-8048-824F979AFCF5Q34645401-E4347983-1716-4757-9304-494D82093EE4Q35174754-74F7CCC2-6A93-4CC4-9048-417BD19A8481Q35798986-7AB498CB-8C4A-47DE-9152-5B6D61C2265EQ36256459-91C6B301-7799-4A81-AB86-1CC07A98EC8BQ36567448-C7011A0B-D32D-4F1D-BCB8-24A6DB36D057Q36695629-11163C54-DF5F-415C-8554-86DAC9C7EBD6Q36708792-FEDE8ED0-2B1F-4636-90F5-F1E935215A85Q36718905-2B2EE06F-5275-4B7E-B57E-E2D16A99B289Q36910465-9DA204D4-69F4-407F-A383-E591B953B567Q37061769-C28F304A-3E1E-48F4-A227-23629781CC49Q37283724-95E44465-196F-4DF1-8B8A-ED2C24F33AF6Q37604481-D3C19B65-DCC6-4E63-95D2-D2E41D5B773BQ37703163-7E1ECDEA-D9AB-4F5E-A753-E5DE48C2D956Q37889984-2DCBBA9C-AC5F-439F-B6C6-32E1562FE013Q37984189-F26CEF25-F0C2-4573-B19D-D8812B6B1C1BQ38017593-986DA07D-7FC4-4874-9FC2-7B475BC9CD15Q38036690-05AEB3A7-6BF4-40F6-923D-153EC4E95794Q38089935-8403FA94-343E-4E92-A67F-23928278416CQ38176758-B54D9111-CF01-4E34-991A-50079C77468CQ38212231-663937AB-540A-4138-9C64-98A7ACFC363CQ38212571-66F335C9-B58D-4BF1-85CF-87C5768B3D1BQ38227030-184D04BE-1F10-4014-9901-C1BE11E6F35CQ38254639-DB1D14D8-16DC-4FD8-9A4D-986D5B911DA6Q38283918-2A675266-93B4-43E2-A1C7-6AC6492D121FQ38544772-D3E7C70C-209C-44B7-98FA-A8C220705258Q38661079-FB1F15D6-B681-467C-B95D-87ED8AE019B1Q38797560-56A16304-49AE-4F9B-ADEF-901FBD062BF9Q39084400-2CAEB7D6-31D8-468B-A984-877D0D6AD2E6Q39183386-7C84399F-7EFF-4203-B357-8BC910E0F12BQ41041538-8F317131-CAEF-4664-85BC-1E0892F5C77FQ41220895-95E83C84-481B-4936-96D3-EDACA6C8540F
P2860
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
DNA vaccine encoding prostatic ...... ith recurrent prostate cancer.
@ast
DNA vaccine encoding prostatic ...... ith recurrent prostate cancer.
@en
DNA vaccine encoding prostatic acid phosphatase
@nl
type
label
DNA vaccine encoding prostatic ...... ith recurrent prostate cancer.
@ast
DNA vaccine encoding prostatic ...... ith recurrent prostate cancer.
@en
DNA vaccine encoding prostatic acid phosphatase
@nl
prefLabel
DNA vaccine encoding prostatic ...... ith recurrent prostate cancer.
@ast
DNA vaccine encoding prostatic ...... ith recurrent prostate cancer.
@en
DNA vaccine encoding prostatic acid phosphatase
@nl
P2093
P2860
P1476
DNA vaccine encoding prostatic ...... ith recurrent prostate cancer.
@en
P2093
Brian M Olson
Douglas G McNeel
Edward J Dunphy
James G Davies
Jordan T Becker
Laura E Johnson
P2860
P304
P356
10.1097/CJI.0B013E3181DDA23E
P577
2010-07-01T00:00:00Z